Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia. The expansion now includes Bangladesh, Pakistan, Nepal, and Sri Lanka, significantly increasing the company's addressable market to an estimated $13.0 billion. This strategic move supports the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions.
The expanded territory allows Co-Diagnostics to tap into densely populated regions with growing healthcare needs. The company's molecular diagnostics technologies are designed for the detection and analysis of nucleic acid molecules, which are critical for diagnosing infectious diseases and other conditions. The CoSara PCR Pro(R) platform, once approved, is expected to provide rapid and accurate testing at the point of care, addressing a significant gap in healthcare infrastructure across South Asia.
Co-Diagnostics, based in Utah, develops, manufactures, and markets state-of-the-art diagnostics technologies. Its proprietary technology enables the design of specific tests for its point-of-care platform and the identification of genetic markers for applications beyond infectious disease. The expansion into new markets underscores the company's commitment to global health and its strategy to leverage joint ventures for regional growth.
For more information about Co-Diagnostics, visit https://co-dx.com/. The full press release is available at https://ibn.fm/2aATV.
